Revance Therapeutics, Inc. (RVNC) is a biotechnology company in the midst of transforming the aesthetics and therapeutic markets with innovative and proprietary products. With its headquarters in Nashville, Tennessee, USA, the company is publicly traded and listed on the NASDAQ Stock Market.
Revance Therapeutics specializes in the development and commercialization of innovative neuromodulators for treating aesthetic and therapeutic conditions. The company’s primary focus lies within the realm of skin and facial aesthetics, eye conditions, and neurology. Revance’s flagship product, DaxibotulinumtoxinA for Injection (DAXI), has propelled the company to the forefront of the aesthetic and therapeutic markets. This prolonged-action product offers marked advantages over competitors, including longer-lasting results for patients and a significantly reduced frequency of treatments.
Established in 1999, Revance Therapeutics has strived for over two decades to elevate patient experiences and redefine the standard of care in aesthetics and therapeutics. To accomplish their mission, they have assembled a team of diversely talented individuals dedicated to excellence in patient care and innovation.
Revance’s impressive research pipeline reflects their commitment to ground-breaking innovation. It includes products being developed for various indications, including moderate to severe glabellar lines, cervical dystonia, plantar fasciitis, and the unique FDA-approved therapeutic use of DAXI in upper limb spasticity.
Revance Therapeutics is ever-evolving, constantly investing in education, research, training, and technology to advance their mission. With a rigorous focus on science and quality, they dedicate their pursuits to delivering innovative, safe, and efficacious solutions for both aesthetic and therapeutic purposes.
As of 2020, the company employs over 350 people and is led by Mark Foley, who brings more than 25 years of experience in the medical aesthetics and pharmaceuticals industry. Revance’s commitment to strategic partnerships and collaborations with leading medical institutions and experts in the field has enabled the company to push boundaries and continue to deliver pioneering solutions in aesthetics and therapeutics.
In conclusion, Revance Therapeutics, Inc. (RVNC) is a distinguished player in the field of biotechnology, with a unique focus on aesthetics and therapeutics. Their revolutionary approach to neuromodulator development and clinical research has made them a company full of potential that the industry and investors are closely watching. With their staples being originality, quality, and patient satisfaction, this promising company is well on its way to reshaping the future of the aesthetic and therapeutic markets.